K. Gottesdiener

发表

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

Lawrence J Hickey, D. Bloomfield, JT Kost, 2008, Clinical pharmacology and therapeutics.

Suppression of Niacin‐induced Vasodilation with an Antagonist to Prostaglandin D2 Receptor Subtype 1

G. O'neill, F. Liu, I. de Lepeleire, 2007, Clinical pharmacology and therapeutics.

Effect of L-000845704, an (cid:1) V (cid:2) 3 Integrin Antagonist, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women

R. Recker, K. Cerchio, M. Murphy, 2005 .

W. Zeng, W. Smith, G. Herman, 2006 .

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

G. O'neill, F. Liu, H. Greenberg, 2008, Clinical pharmacology and therapeutics.

Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D 2 Receptor

H. Greenberg, K. Metters, J. Wagner, 2007 .

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.

G. O'neill, F. Liu, J. Wagner, 2007, Clinical pharmacology and therapeutics.

Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.

J. Paolini, A. Bergman, B. Yi, 2006, International journal of clinical pharmacology and therapeutics.

Potent and Selective Agonism of the Melanocortin Receptor 4 With MK‐0493 Does Not Induce Weight Loss in Obese Human Subjects: Energy Intake Predicts Lack of Weight Loss Efficacy

G. Bray, S. Heymsfield, S. Heymsfield, 2009, Clinical pharmacology and therapeutics.

Assessment of pharmacokinetic interactions between ezetimibe and cyclosporine

J. Paolini, A. Bergman, T. Kosoglou, 2005 .

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet

K. Brune, M. Laurenzi, J. Schwartz, 2002, Clinical pharmacology and therapeutics.

Individual and Combined Effects of Peroxisome Proliferator‐Activated Receptor α and γ Agonists, Fenofibrate and Rosiglitazone, on Biomarkers of Lipid and Glucose Metabolism in Healthy Nondiabetic Volunteers

Margaret S. Wu, J. Miller, D. Moller, 2005, Journal of clinical pharmacology.

MK‐0966, a cyclooxygenase‐2 (COX‐2) specific inhibitor, had no effect on the anti‐platelet activity of low‐dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation

H. Greenberg, M. Huntington, P. Wong, 1999 .

The effect of MK-0524, a prostaglandin D2 receptor antagonist, on prostaglandin D2-induced nasal airway obstruction in healthy volunteers

P. Deutsch, K. Gottesdiener, K. Mazina, 2007, European Journal of Clinical Pharmacology.